In conclusion:
-Trial data being leveraged to understand #Alzheimer, even when trials fail, is great
-Findings on CSF α-synuclein copathology align with our (& others’) ante-postmortem observations
-Hopefully #gantenerumab trial data will be shared with the research community (eg: A4 study)
(6/6)
Since #PART & #Alzheimer share the same type of tau pathology / tangle, the key difference is the absence of amyloid pathology in PART. This has parallels what we observe upon amyloid clearance with anti-amyloid antibodies, such as #gantenerumab.
(4/6)
They found that #α-synuclein #co-pathology was associated with accelerated clinical cognitive decline compared with α-synuclein–negative cases in #gantenerumab treated patients.
More details here: www.alzforum.org/news/confere...
#Alzforum
(2/6)
From the many groundbreaking advances at #ADPD2026 I highlight the following presentation tackling the relevance of #copathology in #Alzheimer:
→Using #gantenerumab trial data the Roche team did a retrospective analysis of CSF samples assessing α-synuclein co-pathology
(1/6)
November 2022 update with #gantenerumab from @Roche
x.com/nvillain_alz/s…
I estimated the standard errors of the #gantenerumab phase 3 trial from the p-value (assuming a one-side t-test) & the CDR-SB effect size, & made assumptions of the completed group size of each arm with a 10% attrition rate: from the press release
3/5 While new results are soon expected from @Roche and @genentech with #gantenerumab, and next year from @LillyPad with #donanemab, we hope it will help to put all these p-values and percentages of reduction of cognitive decline into perspective
